Patents by Inventor Margot O'Toole
Margot O'Toole has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8906375Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: November 22, 2010Date of Patent: December 9, 2014Assignee: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Publication number: 20140286959Abstract: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies.Type: ApplicationFiled: November 2, 2012Publication date: September 25, 2014Applicant: PFIZER Inc.Inventors: Martin Hegen, Deborah Young, Heath Guay, Kyriaki Dunussi-Joannopoulos, Sudhakar Sridharan, Annette Diehl, Gail Comer, Margot O'Toole, Jean Beebe, Robert Fogel, Marek Honczarenko, David Beidler, Padmalatha S. Reddy, David J. von Schack
-
Publication number: 20120276102Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.Type: ApplicationFiled: May 14, 2012Publication date: November 1, 2012Applicant: WYETH LLCInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, Margot O'TOOLE, Heath M. GUAY, Karissa K. ADKINS, Amy Arlene WEAVER, Sadhana JAIN, Maya ARAI
-
Patent number: 8178097Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.Type: GrantFiled: May 26, 2009Date of Patent: May 15, 2012Assignee: Wyeth LLCInventors: Laird Bloom, Davinder Gill, Yulia Vugmeyster, Deborah A. Young, Margot O'Toole, Heath M. Guay, Karissa K. Adkins, Amy Arlene Weaver, Sadhana Jain, Maya Arai
-
Publication number: 20110212099Abstract: The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one of IL-17A, IL-17F, or IL-23Type: ApplicationFiled: March 15, 2011Publication date: September 1, 2011Applicant: Wyeth LLCInventors: Spencer C. LIANG, Lynette A. Fouser, Margot O'Toole
-
Publication number: 20110091478Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: November 22, 2010Publication date: April 21, 2011Applicant: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Patent number: 7846444Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: May 29, 2009Date of Patent: December 7, 2010Assignee: Wyeth LLCInventors: Lynette Fouser, Margot O'Toole, Deborah P. Luxenberg, Martin Hegen
-
Patent number: 7811567Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: GrantFiled: February 20, 2007Date of Patent: October 12, 2010Assignee: Wyeth LLCInventors: Lynette A. Fouser, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Publication number: 20100075329Abstract: The present invention provides human binding proteins and antigen-binding fragments thereof that specifically bind to the human interleukin-21 receptor (IL21R), and uses therefore. The invention further provides methods to predict whether the binding proteins of the invention may take on agonistic activities in vivo and produce a cytokine storm. In addition, the invention provides methods for determining whether an anti-IL21R binding protein is a neutralizing anti-IL21R binding protein, based on the identification of several IL21-responsive genes. The binding proteins can act as, e.g., antagonists of IL21R activity, thereby modulating immune responses in general, and those mediated by IL21R in particular.Type: ApplicationFiled: September 23, 2009Publication date: March 25, 2010Inventors: Margot O'Toole, Yongjing Guo, Renee Ramsey, Laird Bloom
-
Patent number: 7667020Abstract: The present invention provides novel isolated BFLP1698 polynucleotides and polypeptides encoded by the BFLP1698 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP1698 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP1698 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP1698 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: GrantFiled: April 17, 2007Date of Patent: February 23, 2010Assignee: WyethInventors: Margot O'Toole, William Martin Mounts, Negin Shojaee
-
Publication number: 20100015162Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: May 29, 2009Publication date: January 21, 2010Applicant: WyethInventors: Lynette A. FOUSER, Martin Hegen, Deborah P. Luxenberg, Margot O'Toole
-
Publication number: 20090298081Abstract: The present invention provides binding proteins and antigen-binding fragments thereof, including human antibodies, that specifically bind to the human interleukin-21 receptor (IL-21R), and methods of using them. The binding proteins can act as, e.g., antagonists of IL-21R activity, thereby modulating immune responses in general, and those mediated by IL-21R in particular. The disclosed compositions and methods may be used, e.g., in diagnosing, treating, and/or preventing IL-21R-associated disorders, e.g., inflammatory disorders, autoimmune diseases, allergies, transplant rejection, and other immune system disorders.Type: ApplicationFiled: May 26, 2009Publication date: December 3, 2009Applicant: WYETHInventors: Laird BLOOM, Davinder GILL, Yulia VUGMEYSTER, Deborah A. YOUNG, Margot O'TOOLE, Heath M. GUAY, Karissa K. ADKINS, Amy Arlene WEAVER, Sadhana JAIN, Maya ARAI
-
Publication number: 20090263817Abstract: The present invention is directed to novel methods for diagnosis and prognosis of Systemic lupus erythematosus by identifying differentially expressed genes. Moreover, the present invention is also directed to methods that can be used to screen test compounds and therapies for the ability to inhibit systemic lupus erythematosus. Additionally, methods and molecule targets (genes and their products) for therapeutic intervention in systemic lupus erythematosus are described.Type: ApplicationFiled: May 4, 2009Publication date: October 22, 2009Applicant: WyethInventors: Margot O'TOOLE, Holly M. Legault
-
Publication number: 20090098132Abstract: The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP0169 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: ApplicationFiled: September 23, 2008Publication date: April 16, 2009Applicants: Wyeth, Genetics Institute, LLCInventors: Margot O'Toole, William Martin Mounts, Negin Shojaee
-
Patent number: 7491513Abstract: The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP0169 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: GrantFiled: February 15, 2006Date of Patent: February 17, 2009Assignee: WyethInventors: Margot O'Toole, William Martin Mounts, Negin Shojaee
-
Publication number: 20080031882Abstract: The present application provides methods of modulating immune responses by using IL-22 in combination with at least one of IL-17A, IL-17F, or IL-23 or by using an IL-22 antagonist, such as an antibody or a soluble receptor or a binding protein, in combination with an antagonist of at least one of IL-17A, IL-17F, or IL-23Type: ApplicationFiled: June 18, 2007Publication date: February 7, 2008Inventors: Spencer Liang, Lynette Fouser, Margot O'Toole
-
Publication number: 20080009008Abstract: The present invention provides novel isolated BFLP1698 polynucleotides and polypeptides encoded by the BFLP1698 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP1698 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP1698 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP1698 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: ApplicationFiled: April 17, 2007Publication date: January 10, 2008Applicant: WyethInventors: Margot O'Toole, William Mounts, Negin Shojaee
-
Publication number: 20070258982Abstract: The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22) and methods of using those antibodies, for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders.Type: ApplicationFiled: February 20, 2007Publication date: November 8, 2007Inventors: Lynette Fouser, Martin Hegen, Deborah Luxenberg, Margot O'Toole
-
Publication number: 20070212701Abstract: The present invention is directed to the identification of novel targets for therapeutic intervention and prevention of ischemia and reperfusion injury resulting from hypoxia, stroke, heart attack, chronic kidney failure or organ transplantation. In particular, the present invention is directed to the identification of novel targets for the prevention of reperfusion injury following organ transplantation. The present invention is further directed to methods of high-throughput screening for test compounds capable of inhibiting activity of proteins encoded by the novel targets by combining the test compounds and the protein and detecting binding. Moreover, the present invention is also directed to methods that can be used to assess the efficacy of test compounds and therapies for the ability to inhibit organ damage resulting from reperfusion injury. Methods for determining the prognosis of long term organ survival in a subject having an organ transplant are also described.Type: ApplicationFiled: September 11, 2006Publication date: September 13, 2007Inventors: Margot O'Toole, Holly Legault, Allan Kirk
-
Publication number: 20060228356Abstract: The present invention provides novel isolated BFLP0169 polynucleotides and polypeptides encoded by the BFLP0169 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP0169 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP0169 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP0169 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.Type: ApplicationFiled: February 15, 2006Publication date: October 12, 2006Applicant: WyethInventors: Margot O'Toole, William Mounts, Negin Shojaee